#South Korea #Seoul #Daewoong #Bersiporocin #IPF Drug

Daewoong Pharmaceutical Unveils Comprehensive Data on 104 IPF Patients at ERS 2026 Conference

Daewoong Pharmaceutical, co-led by Seongsoo Park and Changjae Lee, showcased critical findings on the baseline characteristics of 104 patients involved in their global Phase 2 clinical trial for the idiopathic pulmonary fibrosis (IPF) drug candidate, Bersiporocin (DWN12088), during the recent European Respiratory Society (ERS) Congress 2026 held in Barcelona, Spain. This trial aims to provide further insights into a condition that poses significant challenges in clinical management.

Key Findings from the Clinical Trial

During the conference on September 6, 2026, Daewoong presented a detailed analysis of the patient demographics and their clinical profiles. Altogether, the trial enrolled patients from both South Korea (55 patients, 52.9%) and the United States (49 patients, 47.1%). Among these patients, a noteworthy 71 individuals (68.3%) were under existing antifibrotic treatments, while 33 patients (31.7%) were not receiving any such therapy.

The analysis provided a thorough overview of various clinical indicators. The statistical data indicated that the mean forced vital capacity (FVC) was approximately 77% of what is predicted for healthy individuals, while the mean diffusing capacity of the lungs for carbon monoxide (DLCO) stood at around 51% predicted. These figures highlight the spectrum of pulmonary function that IPF patients experience, underscoring the severity of this progressive disease.

Understanding the Mechanism of Bersiporocin

Bersiporocin operates as a first-in-class prolyl-tRNA synthetase (PRS) inhibitor, particularly pivotal in the context of healing and reparative processes compromised by IPF. By selectively inhibiting PRS, it aims to mitigate the excessive collagen production typically observed in fibrotic conditions. One of the trial's strengths is its design, which mirrors real-world scenarios by incorporating patients treated with other antifibrotic agents and those who aren’t, thus enriching the trial’s applicability.

Professor Moo Suk Park from Severance Hospital commented, "This comprehensive study provides valuable context surrounding the baseline characteristics of patients enrolled in both South Korea and the U.S. with idiopathic pulmonary fibrosis. Understanding these profiles will be crucial for interpreting later efficacy and safety outcomes for Bersiporocin."

The Journey Ahead for Bersiporocin

As this Phase 2 trial progresses toward its conclusion, Daewoong is positioned to share more impactful results. The company's strategy includes a randomized, double-blind, placebo-controlled approach where participants receive Bersiporocin or a placebo for a duration of 24 weeks. This meticulous study design, allowing the co-administration of established antifibrotic therapies like pirfenidone or nintedanib, reflects a commitment to incorporating diverse patient experiences.

Given its innovative approach and promising data, Bersiporocin has already attained Orphan Drug Designation and Fast Track status from the US FDA, alongside similar designations from the European Medicines Agency (EMA). Such recognitions not only propel the drug’s development but also emphasize the importance of expanding therapeutic options for IPF.

Seongsoo Park concluded a press session stating, "Successfully completing patient enrollment for this global Phase 2 trial marks a significant achievement for Bersiporocin. We eagerly anticipate revealing the top-line results in the first half of 2027, which will guide further global development efforts."

In summary, this clinical endeavor reflects Daewoong Pharmaceutical's innovation and dedication toward improving the lives of patients battling IPF. The presentation at ERS 2026 serves as a stepping stone in understanding and ultimately addressing the challenges posed by this debilitating disease.